Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Aegleio

Merck’s accelerator to take start-ups to Silicon Valley

Will expand the reach of its Darmstadt and Nairobi programmes

Sanofi reception

Sanofi boosted by iGlarLixi trials at ADA

Combination of Lantus and Lyxumia showed greater efficacy in controlling type 2 diabetes

- PMLiVE

Roche picks up European rights to diabetes implant

Will distribute Senseonics' Eversense CGM System in Germany, Italy and the Netherlands

- PMLiVE

Medtronic and Qualcomm to work on new diabetes sensors

Will initially collaborate on a single-use wireless continuous glucose monitoring system

Sanofi reception

FDA panel backs Sanofi’s insulin/GLP-1 agonist combo

iGlarLixi secures endorsement despite concern over its dosing and delivery device

Eli Lilly HQ

Lilly planning 20 new launches by 2023

Will focus on diabetes, immunology, oncology, neurodegeneration and pain

- PMLiVE

FDA advisors back Novo Nordisk’s IDeglira combination

Unanimous vote is a step forward for the Tesiba-Victoza injection

National Institute for Health and Care Excellence NICE logo

NICE backs freer use of SGLT2 inhibitors for diabetes

Recommendation positions Invokana, Forxiga and Jardiance as first-line treatments

- PMLiVE

Merck agrees African digital cooperation deal

Will collaborate with Germany's GIZ on new solutions for the continent

Meet Nokia, the digital health company

Former mobile phone giant acquires connected health firm Withings for €170m

- PMLiVE

Merck drops once-weekly diabetes drug in US and EU

Says decision is due to “business reasons” not safety or efficacy issues

AstraZeneca AZ

AstraZeneca launches diabetes lifestyle campaign

Aims to support people with type 2 diabetes in becoming more active

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links